The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach - 09/08/11
Skokie and Chicago, Illinois
Abstract |
Psoriatic arthritis is a common inflammatory arthritis associated with psoriasis, occurring in 5% to 40% of patients with cutaneous disease. Recently, there has been an increased appreciation of the need to use an integrated approach to these 2 diseases, considering both entities when determining therapeutic choices. In this review, the available therapeutic options for psoriatic arthritis are considered, along with the potential benefit that these medications may have for cutaneous psoriasis. Finally, a conceptual model for the therapy of psoriasis and psoriatic arthritis, the Four Quadrant Model, is presented as a simplified framework to use when considering treatment for psoriatic disease.
Le texte complet de cet article est disponible en PDF.Plan
Supported by Amgen Inc and Wyeth Research. This review was investigator initiated. Financial support for the manuscript was provided by Amgen; all other aspects were performed independently of Amgen. Conflicts of interest: Dr Gordon has received research support and honoraria from the following companies: Abbott, Amgen, Biogen, Centocor, and Genentech. He received an honorarium from Amgen for this manuscript work. Dr Ruderman has received research grants from Abbott Immunology, Amgen, Bristol Meyers Squibb, Centocor, Genentech, IDEC, Merck, and Pfizer. He has consulted for Abbott Immunology, Amgen, Bristol Meyers Squibb, Genentech, Merck, and Wyeth, and has served on speakers’ bureaus for Abbott Immunology, Amgen, Centocor, Merck, Pfizer, and Wyeth. He does not own stock in any of these companies. Reprints not available from the authors. |
Vol 54 - N° 3S2
P. S85-S91 - mars 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?